The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

The company's revenue jumped 77% in Q3 to reach $401.6 million in Q3 2024, alongside a net income of $75.6 million. It now ...

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

The following is a summary of “Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

"Full House" actor Dave Coulier, 65, revealed he has stage 3 non-Hodgkin's lymphoma. ( People) The latest tally of the ...